Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

摘要: Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been standard care stroke prevention in patients AF since early 1990s. They are very effective stroke, but limited by factors such as drug-drug interactions, food slow onset offset action, haemorrhage need routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants developed potential replacements VKAs AF. Most small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or Xa rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs predictable pharmacokinetics allow fixed dosing without laboratory monitoring. Dabigatran etexilate, first these be approved United States Food Drug Administration European Medicines Agency non-valvular AF, represents safe alternative VKAs. Under auspices Regional Anticoagulation Working Group, multidisciplinary group experts thrombosis haemostasis from Central Eastern Europe, expert panel expertise convened discuss practical, clinically important issues related long-term use The practical information reviewed this article will help clinicians make appropriate option daily clinical practice.